Santhera Reports Results of Idebenone in SYROS Study for Duchenne Muscular Dystrophy

 Santhera Reports Results of Idebenone in SYROS Study for Duchenne Muscular Dystrophy

Santhera Reports Results of Idebenone in SYROS Study for Duchenne Muscular Dystrophy

Shots:

  • The SYROS study involves assessing of respiratory function evolution during periods of treatment with idebenone (900 mg/day) (On-Idebenone) compared to period without idebenone treatment (Off-Idebenone) in 18 patients with DMD not using glucocorticoids under Expanded Access Programs following P-III DELOS study, published in Neuromuscular Disorders
  • The SYROS study results demonstrated long-term efficacy in slowing respiratory function loss (4.2yrs.), 50% reduction in in FVC%p in Off-Idebenone patients (-7.4% vs -3.8%), reduction in PEF%p (-5.9% vs -1.9%), reduction in the rate of bronchopulmonary AE (0.10 vs 0.33 events per person-year), reduction in rate of hospitalization (0.06 vs 0.15 events per person-year)
  • Idebenone is a chemical analog of benzoquinone and a co-factor for quinone oxidoreductase (NQO1) and has received the ODD designation in Europe, the US, Switzerland & Australia and an FT designation by the US FDA

Click here to­ read full press release/ article | Ref: Santhera | Image: Santhera

Tuba Khan

Tuba Khan is Senior Editor at PharmaShots. She is curious, creative, and passionate about recent updates and innovation in the Life sciences industry. She covers Biopharma, MedTech, and Digital health segments. Tuba also has an experience of digital and social media marketing and runs the campaigns independently. She can be contacted on tuba@pharmashots.com

Related post